Provectus eliminates Series B Preferred Stock, increases Series D-1 authorized shares

PROVECTUS BIOPHARMACEUTICALS, INC.

Filed Certificate of Elimination for Series B Convertible Preferred Stock; all shares converted to common on Aug 25, 2021.
Filed Certificate of Amendment increasing authorized Series D-1 Preferred Stock from 9,441,000 to 11,241,000 shares.
Both actions effective March 30, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.